Assigned Patent Rights. Cerulean shall have the sole right, at its own expense and in its own name, to prepare, file, prosecute and maintain the Assigned Patent Rights. If Cerulean determines to discontinue the prosecution or maintenance of any patent application or patent within such Assigned Patent Rights, Cerulean shall promptly notify Calando, sufficiently in advance of any deadlines to ensure that no rights with respect thereto are lost, and thereupon, Calando shall have the right, at its own expense, to prosecute and maintain any such Patent Right.
Assigned Patent Rights. The Lender shall have received duly executed copies of the Patent Assignment Agreement and Patent License.
Assigned Patent Rights. The Party prosecuting and maintaining the Joint Patent Right shall have the primary right, but not the obligation, to take action to obtain a discontinuance of infringement or bring suit against a Third Party infringer of such Patent Right. The enforcing Party shall bear all expenses of such action or suit.
Assigned Patent Rights. Upon assignment, BI shall have the right but not the obligation, of preparing, filing, prosecuting, maintaining and defending Patent Rights within the Collaboration Intellectual Property assigned and transferred, wholly or in part, as the case may be, by CureVac to BI in accordance with Section 9.3 (the "Assigned Patent Rights"), anywhere in the Territory, and shall keep CureVac advised of the status of prosecution of all such Patent Rights, and shall give CureVac before filing or response to office actions, as applicable, reasonable opportunity to review and comment upon the text of any applications or amendments or other substantive actions for such Patent Rights. BI shall not unreasonably refuse to address any of CureVac's comments made in accordance with this Section 9.5.3.
Assigned Patent Rights. Relypsa shall have the first right, but not the obligation, to file, prosecute, defend, maintain and enforce the Assigned Patent Rights before all patent authorities in the Territory and shall be responsible for all costs and expenses, and shall be entitled to retain all recoveries, related thereto. If Relypsa determines in its sole discretion to not file, prosecute, defend, maintain or enforce any patent application or patent within the Assigned Patent Rights that covers or claims any invention within the (a) ILY105 Program in any country and as of such time Relypsa has not satisfied all milestone payment obligations under Section 6.3 of this Restated Agreement, or (b) ILY102 Program or ILY103 Program in any country, then in each such case Relypsa shall provide Ilypsa with at least thirty (30) days prior written notice to any required submission or payment, as applicable, to the patent authority of such country and shall provide Ilypsa with the right and opportunity to assume responsibility and control over the filing, prosecution, defense, maintenance and enforcement of any such patent application or patent. If Ilypsa assumes responsibility and control over such patent application or patent within such program (each such patent or application an “Assumed Patent”), it shall so notify Relypsa in writing within such thirty (30) days, and thereafter be responsible for all costs and expenses, and shall be entitled to retain all recoveries, related thereto. For the sake of clarity, for purposes of this Section 8.1, assumption of responsibility and control over the filing, prosecution, defense, maintenance and enforcement of a patent application or patent means assumption of handling and decision-making with respect to filing, prosecution, defense, maintenance and enforcement of such patent application or patent, but not an assignment of ownership of that patent application or patent from Relypsa to Ilypsa; however, Relypsa will reasonably cooperate with Ilypsa and take such actions as are necessary to permit Ilypsa to effectuate and exercise such responsibility and control. In addition, following Relypsa’s satisfaction of all milestone payment obligations under Section 6.3 of this Restated Agreement, upon the written request of Relypsa, Ilypsa shall revert back to Relypsa all responsibility and control over the filing, prosecution, defense, maintenance and enforcement of any Assumed Patent within the ILY105 Program, and Ilypsa shall have no further rights with...
Assigned Patent Rights. “Assigned Patent Rights” shall have the meaning specified in Section 1.1(a) of the Agreement.
Assigned Patent Rights. Licensor shall use reasonable and customary care with respect to the prosecution and maintenance of the Assigned Patent Rights [***] has [***] the [***] or [***] the [***] that is [***] the [***]. Absent Licensor’s recklessness or willful
Assigned Patent Rights. Country Application No. Patent No. -------------------------------------------------------------------------------- Japan 1998-509541 -------------------------------------------------------------------------------- Japan 2000-507371 -------------------------------------------------------------------------------- USA 09/485,909 6,670,369 -------------------------------------------------------------------------------- Japan 2000-592001 -------------------------------------------------------------------------------- USA 10/098,922 -------------------------------------------------------------------------------- USA 09/023,544 6,001,852 -------------------------------------------------------------------------------- USA 09/023,543 5,980,914 -------------------------------------------------------------------------------- USA 09/023,542 5,994,323 -------------------------------------------------------------------------------- USA 10/7 17,182 -------------------------------------------------------------------------------- Execution Version DERIVATIVES AGREEMENT This Derivatives Agreement (this "Agreement") is entered into effective as of July 28, 2004 ("Effective Date"), by and among P.N. Gerolymatos S.A., a corporation organized under the laws of Greece ("PNG") and Prana Biotechnology Limited, a corporation organized under the laws of Australia ("Prana").
Assigned Patent Rights. Country Application No. Patent No. -------------------------------------------------------------------------------- Japan 1998-509541 -------------------------------------------------------------------------------- Japan 2000-507371 -------------------------------------------------------------------------------- USA 09/485,909 6,670,369 -------------------------------------------------------------------------------- Japan 2000-592001 -------------------------------------------------------------------------------- USA 10/098,922 -------------------------------------------------------------------------------- USA 09/023,544 6,001,852 -------------------------------------------------------------------------------- USA 09/023,543 5,980,914 -------------------------------------------------------------------------------- USA 09/023,542 5,994,323 -------------------------------------------------------------------------------- USA 10/717,182 -------------------------------------------------------------------------------- Schedule 1.20 PNG Patent Rights (PNG Territories, Option Territories and Lundbeck Territories) Title: Use of the chelating agent clioquinol for the manufacture of the pharmaceutical composition for the treatment of Alzheimer's disease -------------------------------------------------------------------------------- Country Application No. Patent No. -------------------------------------------------------------------------------- Austria AT E 205086 T -------------------------------------------------------------------------------- Belgium BE 959888 T -------------------------------------------------------------------------------- Switzerland/Liechtenstein CH 959888 X -------------------------------------------------------------------------------- Germany DE 69706566 T -------------------------------------------------------------------------------- Denmark DK 959888 T -------------------------------------------------------------------------------- Spain ES 2192319 T -------------------------------------------------------------------------------- Finland FI 959888 T -------------------------------------------------------------------------------- France FR 959800 X -------------------------------------------------------------------------------- United Kingdom GB 959888 T -------------------------------------------------------------------------------- Greece GR 959800 X -------------------------------------------------------------------------------- Ire...
Assigned Patent Rights. Subject to the terms and conditions of this Agreement and the Reserved Rights, effective as of the Effective Date, Isis hereby agrees to, and hereby does, sell, assign and transfer to Sequenom, and Sequenom hereby agrees to, and hereby does, purchase from Isis, all right, title and interest in and to the Assigned Patent Rights in the Territory, including, without limitation (but subject always to the Reserved Rights), all rights to causes of action and remedies related thereto, including, without limitation, all rights (a) to initiate, prosecute, control and settle any and all proceedings (including, without limitation, the Proceedings) related to past, present or future infringement, misappropriation or violation of the Assigned Patent Rights, (b) to retain all recoveries from any and all such proceedings, and (c) to prosecute, maintain and defend the Assigned Patent Rights (including to respond to and defend any and all interferences, oppositions, reexaminations, inter partes reviews, post grant reviews, and other challenges of any type or nature whatsoever). ***Confidential Treatment Requested
